Yu-chuan Liu
Taoyuan, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
HCH6-1, an antagonist of formyl peptide receptor-1, exerts anti-neuroinflammatory and neuroprotective effects in cellular and animal models of Parkinson's disease.
Journal: Biochemical pharmacology
Published: March 22, 2023
Functional variant rs17525453 within RAB35 gene promoter is possibly associated with increased risk of Parkinson's disease in Taiwanese population.
Journal: Neurobiology of aging
Published: December 30, 2020
(D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model.
Journal: Cell death & disease
Published: April 20, 2020
Alda-1, an activator of ALDH2, ameliorates Achilles tendinopathy in cellular and mouse models.
Journal: Biochemical pharmacology
Published: February 19, 2020
Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations.
Journal: Stem cell research
Published: May 07, 2019
Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade.
Journal: Frontiers in cellular neuroscience
Published: April 10, 2019
PARK14 (D331Y) PLA2G6 Causes Early-Onset Degeneration of Substantia Nigra Dopaminergic Neurons by Inducing Mitochondrial Dysfunction, ER Stress, Mitophagy Impairment and Transcriptional Dysregulation in a Knockin Mouse Model.
Journal: Molecular neurobiology
Published: January 04, 2018
PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway.
Journal: Oncotarget
Published: March 01, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026